Dallas, Texas 02/20/2014 (FINANCIALSTRENDS) – Galena Biopharma Inc (NASDAQ:GALE) has been one of the leading pharmaceuticals which has invested in and has been successful in developing several candidates, which save patients who are suffering from cancer and are no longer responding to current range of cancer products.
Galena BiopharmaInc(NASDAQ:GALE)products which oncologists have evinced great interest in NeuVax, Abstral. GALE is known to develop vaccines which develop the immunity to strains of cancer causing cells. With Abstral GALE has introduced pain management focus to its portfolio.
According to oncologists, Abstral has been effective in helping cancer patients to bear and continue living their lives. One of the main requirements in oncology treatment is keeping the pain out of cancer patients. Abstral, follows a rapid onset approach and brings pain relief. The advantage of this drug is that in situations and scenarios where pain management delivery is not possible intravenously or there is limited access to such services, Abstral has proved to be the most effective alternative. The value of the drug has been its ease of delivery of service and breakthrough in pain cancer patients always suffer from.
Galena BiopharmaInc(NASDAQ:GALE) suggest oncologists should extend the Phase 3 trial of NeuVax, especially for the subset analysis. This is not to deny the value of the current data which is impressive thus far. Oncologists that it does match the sterling standards that another cancer-fighting drug Alimta, an Eli Lilly product whose generic name is pemetrexed, which when it completed its Stage IV trials and proved to have highest efficacy in treatment of non-squamous cell cancer.
Galena BiopharmaInc(NASDAQ:GALE) with the subset analysis for NeuVax will see the statistics established and the opportunity to set up Phase III trial. However, this will be possible only if GALE is able to substantiate it current trial and hope that the trial proves to be positive.